AstraZeneca launches $1.5B annual cost-cutting program, reinvests in R&D

AstraZeneca announced a three-year cost-cutting initiative targeting $1.5 billion in annual savings, with proceeds redirected to R&D. The move signals a strategic shift toward efficiency and pipeline investment, though details on specific cuts remain undisclosed. This is a corporate restructuring with potential implications for the pharma sector's competitive dynamics.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works